| scholarly article | Q13442814 |
| P50 | author | LeAnne M. Fox | Q84361158 |
| P2093 | author name string | Louis D Saravolatz | |
| P2860 | cites work | Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial | Q44210953 |
| Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru | Q44282413 | ||
| Treatment of intestinal parasitic infections: a review of nitazoxanide | Q45712771 | ||
| Nitazoxanide, a nitrothiazolide antiparasitic drug, is an anti-Helicobacter pylori agent with anti-vacuolating toxin activity. | Q54089671 | ||
| Blastocystis hominis: neutral red supravital staining and its application to in vitro drug sensitivity testing | Q28143140 | ||
| Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses | Q28202853 | ||
| Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori | Q28205159 | ||
| Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture | Q28375148 | ||
| Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru | Q34132664 | ||
| Nitazoxanide for the treatment of intestinal protozoan and helminthic infections in Mexico | Q34467413 | ||
| Successful treatment of human fascioliasis with nitazoxanide | Q34750173 | ||
| In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes | Q34822604 | ||
| In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis | Q38859525 | ||
| In vitro and in vivo activities of nitazoxanide against Clostridium difficile | Q39474787 | ||
| Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells | Q40869727 | ||
| Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome | Q43613085 | ||
| Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide | Q43634110 | ||
| Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide | Q43666861 | ||
| Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru | Q43734573 | ||
| In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites | Q44066152 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1173-1180 | |
| P577 | publication date | 2005-03-14 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Nitazoxanide: a new thiazolide antiparasitic agent | |
| P478 | volume | 40 |
| Q45070596 | 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea |
| Q52727646 | 7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors. |
| Q34793715 | A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide. |
| Q39719937 | A day at the pool. |
| Q35840867 | A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides |
| Q34509808 | Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species |
| Q36904890 | Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy |
| Q114397730 | Advances in the Development of Antiviral Compounds for Rotavirus Infections |
| Q37813126 | Alternative therapies for Clostridium difficile infections |
| Q28534669 | An extensive comparison of the effect of anthelmintic classes on diverse nematodes |
| Q24202445 | Anthelmintic drugs for treating ascariasis |
| Q61449726 | Antiamoebic drugs for treating amoebic colitis |
| Q42235188 | Antiparasitic Activity of Mirazid, Myrrh Total Oil and Nitazoxanide Compared to Praziquantel on Schistosoma mansoni: Scanning Electron Microscopic Study |
| Q30352841 | Antiprotozoal Nitazoxanide Derivatives: Synthesis, Bioassays and QSAR Study Combined with Docking for Mechanistic Insight. |
| Q34123709 | Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro |
| Q35322096 | Autophagy in the fight against tuberculosis |
| Q95627233 | Battling COVID-19: using old weapons for a new enemy |
| Q37633859 | Clinical update for the diagnosis and treatment of Clostridium difficile infection |
| Q56342019 | Clinical, environmental, and behavioral characteristics associated with Cryptosporidium infection among children with moderate-to-severe diarrhea in rural western Kenya, 2008-2012: The Global Enteric Multicenter Study (GEMS) |
| Q33276804 | Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide |
| Q36248917 | Community Laboratory Testing for Cryptosporidium: Multicenter Study Retesting Public Health Surveillance Stool Samples Positive for Cryptosporidium by Rapid Cartridge Assay with Direct Fluorescent Antibody Testing |
| Q30363190 | Continuing challenges in influenza. |
| Q46019974 | Cryptosporidiosis from a community swimming pool: outbreak investigation and follow-up study. |
| Q38235444 | Current bioanalytical methods for pharmacokinetic studies of drugs used in neglected tropical diseases |
| Q38023283 | Current state of Clostridium difficile treatment options |
| Q37390538 | Current treatment options for Dientamoeba fragilis infections. |
| Q44765518 | Diarrhea in patients with AIDS. |
| Q99569581 | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| Q36196130 | EFFICACY OF NITAZOXANIDE AGAINST Toxocara canis: LARVAL RECOVERY AND HUMORAL IMMUNE RESPONSE IN EXPERIMENTALLY INFECTED MICE. |
| Q28250954 | Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial |
| Q38875211 | Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats |
| Q36659957 | Emerging therapies in the treatment of Clostridium difficile-associated disease |
| Q87624349 | Enteric infections |
| Q36156094 | Enteric protozoa in the developed world: a public health perspective. |
| Q27470966 | Epidemiology and management of infectious diseases in international adoptees |
| Q42114388 | Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum |
| Q28535341 | Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanide |
| Q35175136 | Future novel therapeutic agents for Clostridium difficile infection |
| Q34212799 | Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the |
| Q33517055 | High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. |
| Q40336243 | In vitro effects of thiazolides on Giardia lamblia WB clone C6 cultured axenically and in coculture with Caco2 cells |
| Q33935398 | In vitro efficacies of nitazoxanide and other thiazolides against Neospora caninum tachyzoites reveal antiparasitic activity independent of the nitro group |
| Q79788515 | In vitro efficacy of nitro- and bromo-thiazolyl-salicylamide compounds (thiazolides) against Besnoitia besnoiti infection in Vero cells |
| Q39860745 | In vitro efficacy of nitro- and halogeno-thiazolide/thiadiazolide derivatives against Sarcocystis neurona |
| Q47797096 | In vivo treatment with nitazoxanide induces anaerobic metabolism in experimental intraperitoneal cysticercosis |
| Q41925193 | Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency |
| Q38198766 | Management of acute infectious diarrhea for children living in resource-limited settings. |
| Q37609111 | Microarray analysis of the human antibody response to synthetic Cryptosporidium glycopeptides |
| Q39976885 | Multiple risk factors associated with a large statewide increase in cryptosporidiosis |
| Q42160883 | N-(5-Nitro-1,3-thia-zol-2-yl)-4-(tri-fluoro-meth-yl)benzamide |
| Q100387979 | Nitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model |
| Q79863382 | Nitazoxanide for rotavirus diarrhoea? |
| Q34251544 | Nitazoxanide for the empiric treatment of pediatric infectious diarrhea |
| Q80534371 | Nitazoxanide in the treatment of Ascaris lumbricoides in a rural zone of Colima, Mexico |
| Q80688787 | Nitazoxanide in the treatment of amoebiasis |
| Q30434600 | Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae |
| Q56562738 | Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57 |
| Q37590577 | Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model |
| Q28483646 | Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis |
| Q28236279 | Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections |
| Q57287856 | Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma |
| Q37390491 | Nitazoxanide: In vitro and in vivo drug effects against Trichuris muris and Ancylostoma ceylanicum, alone or in combination. |
| Q28242385 | Nitazoxanide: a review of its use in the treatment of gastrointestinal infections |
| Q40149924 | Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent |
| Q37678601 | Nitazoxanide: nematicidal mode of action and drug combination studies |
| Q54365687 | Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs. |
| Q90748454 | Norovirus antivirals: Where are we now? |
| Q36012636 | Norovirus gastroenteritis successfully treated with nitazoxanide |
| Q55405974 | Novel Antimicrobials for the Treatment of Clostridium difficile Infection. |
| Q26862449 | Novel approaches and challenges to treatment of central nervous system viral infections |
| Q30241442 | Options for improving effectiveness of rotavirus vaccines in developing countries. |
| Q36581415 | Parasitic infections in transplant recipients |
| Q37158734 | Polymorphic mucin antigens CpMuc4 and CpMuc5 are integral to Cryptosporidium parvum infection in vitro |
| Q58495599 | Potential Therapeutic Agents for Feline Calicivirus Infection |
| Q27487112 | Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide |
| Q95651180 | Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics |
| Q46210511 | Prophylactic and therapeutic efficacy of nitazoxanide against Cryptosporidium parvum in experimentally challenged neonatal calves |
| Q33869159 | Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children |
| Q41547988 | Recommendations from the Brazilian Society of Rheumatology on the diagnosis and treatment of intestinal parasitic infections in patients with autoimmune rheumatic disorders |
| Q26796360 | Role of Marine Natural Products in the Genesis of Antiviral Agents |
| Q34476815 | Role of chemotherapy of taeniasis in prevention of neurocysticercosis |
| Q56347674 | Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum |
| Q35186820 | Serum antibody responses to polymorphic Cryptosporidium mucin antigen in Bangladeshi children with cryptosporidiosis |
| Q64975289 | Solid-State Behavior and Solubilization of Flash Nanoprecipitated Clofazimine Particles during the Dispersion and Digestion of Milk-Based Formulations. |
| Q92995255 | Specific increase of Fusobacterium in the faecal microbiota of neonatal calves infected with Cryptosporidium parvum |
| Q43039343 | Susceptibility in vitro of clinically metronidazole-resistant Trichomonas vaginalis to nitazoxanide, toyocamycin, and 2-fluoro-2'-deoxyadenosine |
| Q56066171 | Sushi in Pregnancy, Parasitic Diseases - Obstetrician Survey |
| Q41633036 | Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro |
| Q40503773 | Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs |
| Q64071513 | The Concept of an Ideal Antibiotic: Implications for Drug Design |
| Q50193112 | The existing drug vorinostat as a new lead against cryptosporidiosis by targeting the parasite histone deacetylases. |
| Q41991627 | The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis |
| Q58428192 | The use of nitazoxanide against the pathogens Ichthyophthirius multifiliis and Aeromonas hydrophila in silver catfish (Rhamdia quelen) |
| Q48613148 | Therapeutic effects of Iranian herbal extracts against Trichomonas vaginalis |
| Q55473211 | Therapeutic effects of Iranian herbal extracts against Trichomonas vaginalis. |
| Q94663712 | Therapeutic potential of Nitazoxanide against Newcastle disease virus: A possible modulation of host cytokines |
| Q39430380 | Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel |
| Q39717911 | Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication |
| Q42740762 | Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication |
| Q92025479 | Thiazolides promote G1 cell cycle arrest in colorectal cancer cells by targeting the mitochondrial respiratory chain |
| Q36347320 | Thiazolides promote apoptosis in colorectal tumor cells via MAP kinase-induced Bim and Puma activation |
| Q28253220 | Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level |
| Q37481436 | Thiazolides: a new class of antiviral drugs |
| Q37277077 | Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. |
| Q34710368 | Treatment of Clostridium difficile infection: recent trial results |
| Q59297377 | Treatment-refractory giardiasis: challenges and solutions |
| Q98288216 | Two-day enema antibiotic therapy for parasite eradication and resolution of symptoms |
| Q40344726 | Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond |
| Q33817389 | Using a health-rating system to evaluate the usefulness of Caenorhabditis elegans as a model for anthelmintic study |
Search more.